Ambassador Froman, Don’t Let the Trans-Pacific Partnership Restrict Access to Affordable Medicine

AARP continues to voice its serious concerns about the current draft of the Trans-Pacific Partnership (TPP), a massive trade agreement that will affect millions of people here in the U.S. and abroad and could set an unfortunate precedent for future trade agreements. The draft agreement contains provisions that add to the profits of the brand-name pharmaceutical industry at the expense of patients and older Americans. In fact, some of the TPP provisions run counter to current U.S. laws that are …

Is the Era of Cheap Generic Drugs About to End?

En español | Prices for generic drugs most commonly used by older Americans fell by the smallest percentage since 2006, with 1 in 4 rising in price — some by more than 1,000 percent, according to a new report from AARP’s Public Policy Institute (PPI). The report looked at 2013 price trends for 280 generic prescription medications widely used by those age 50-plus. The majority of these generics saw price decreases, some of them substantial, but the overall decline slowed …

11 Things We Didn’t Know Last Week

News, discoveries and … fun 1. A flycatcher first glimpsed in 1997 and then collected in 2012 has been confirmed as a new bird species. (Learn more at Futurity) 2. Remarriage is on the rise for Americans ages 55 and older. (Learn more at Pew Research Center) >> Ageless Hollywood Celebs — No Way They’re 70-Plus! 3. A British man lived with a tapeworm moving around in his brain for four years. (Learn more at Mashable) 4. A spoon developed …

FDA Begins New Testing of Generic-Drug Quality

For decades, doctors, drug companies and the Food and Drug Administration have assured us that low-cost prescription generic drugs – which make up an estimated 80 percent of the prescription medicines we take – work just as well as the costlier brand-name drugs they mimic. Except that a growing number of patient complaints, as well as issues over the quality of generics manufactured abroad, have proven that some of them don’t. And it appears the FDA is finally going to …

Supreme Court: Drugmakers’ Pay-for-Delay Deals Can Be Illegal

Deals between brand-name drugmakers and their generic drug competitors that keep cheaper products off the market might illegally prevent competition, the U.S. Supreme Court ruled June 17. In so-called pay-for-delay deals or reverse settlements, a patent holder pays a would-be competitor not to sell a generic version of a drug for a specified period of time. The brand-name manufacturer can continue to charge monopoly prices, and the generic company is compensated for inaction. In Federal Trade Commission v. Actavis, the …

Does a Top Drugmaker’s Playbook Stifle Competition?

If you owned the bestselling prescription drug of all time and its patent was about to expire, how would you prepare for competition from generic drugs? You might look at what Pfizer did when time was running out on its patent for the cholesterol-lowering drug Lipitor, which by 2011 had become the all-time bestselling prescription drug of any kind. And you could save yourself some time by reviewing a new AARP Public Policy Institute case study of Pfizer’s approach. The …